Skip to content
MARKETS / NASDAQ / HYFT
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

MindWalk Holdings Corp. HYFT

6 fiscal years on record · CAD · FY2024 reported · SEC filings only
CAD 24.5M
▲ 0.0% YoY
CAD -30.2M
CAD -7.2M
In brief

What this company does

MindWalk Holdings Corp. is presently traded on the Nasdaq Capital Market with the ticker symbol “HYFT”. The Board of Directors of the Company (the “Board”) previously approved a change in our corporate name from ImmunoPrecise Antibodies Ltd. to MindWalk Holdings Corp., which became effective on September 3, 2025. MindWalk Holdings Corp. is a Bio-Native AI company that applies artificial intelligence proprietary biological pattern analysis and wet-lab capabilities to support therapeutic discovery. The Company develops BioIntelligence infrastructure that life sciences AI, and increasingly agentic AI, requires, which is designed to integrate AI, data, and full-stack wet lab capabilities into one connected discovery ecosystem. At its core is HYFT® Technology, the Company’s patented, function-aware representation of biology, refined over 20 years of curation into a biological representation of 660 million patterns and 25 billion relationships spanning sequence and structural biology.

Written from the business description in MindWalk Holdings Corp.'s annual report to the U.S. Securities and Exchange Commission, filed 23 July 2026. Every sentence was checked against that document before publication.

Growth
CAD 24.5M
Revenue, FY2024 · full 6-year series below
Revenue CAD M Net income CAD M
FY2024 · Revenue 24.5 · Net income -30.2
10M20M-20M201920202021202220232024
Compound annual growth
+8.2%
+11.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +11.8% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−123 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Net -123.3%
-50%-100%201920202021202220232024
ROE

Not available in our data for this period.

Cash & shareholders
returned in FY2024 · dividends + net buybacks
Free cash flow CAD M
FY2024 · FCF -7.2
-8M-16M201920202021202220232024

Total assetsCAD 44.4M
CashCAD 10.8M
Current ratio2.08×

Not available: we don't have the total debt figure for this period.

The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · CAD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202420232022202120202019
Revenue CAD B0.00.00.00.00.00.0
Operating income CAD B······
EBITDA CAD B······
Income tax CAD B−0.0−0.0−0.00.00.0−0.0
Net income CAD B−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow CAD B−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted CAD −0.91−1.02−1.07−0.85··
Dividend / sh CAD ······
Payout %······
ROE %······
Shares out B0.050.030.030.020.020.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Provenance
Company facts, as filed
How we verify · 0 failures in 28 reconciliationsAUDITED

Reconciled in 6 of 19 fiscal years. 67 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code A1
Fiscal year endsApril 30
Data on record since2019

Share this section

Download image